Faculty Opinions recommendation of Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Year: 2019
Type: peer-review
Author: Anna Rita Migliaccio
Institution: University of Bologna
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4245629455